Market cap is the total market value to buy the whole company. It is equal to the share price times the number of Shares Outstanding (EOP). HeXun Biosciences Co's share price for the quarter that ended in Dec. 2024 was NT$66.5. HeXun Biosciences Co's Shares Outstanding (EOP) for the quarter that ended in Dec. 2024 was 46.0 Mil. Therefore, HeXun Biosciences Co's market cap for the quarter that ended in Dec. 2024 was NT$3,059.9 Mil.
HeXun Biosciences Co's quarterly market cap
increased
from Dec. 2023 (NT$2,980.8 Mil) to Jun. 2024 (NT$3,454.6 Mil) but then
declined
from Jun. 2024 (NT$3,454.6 Mil) to Dec. 2024 (NT$3,059.9 Mil).
HeXun Biosciences Co's annual market cap
increased
from Dec. 2022 (NT$0.0 Mil) to Dec. 2023 (NT$2,980.8 Mil) and
increased
from Dec. 2023 (NT$2,980.8 Mil) to Dec. 2024 (NT$3,059.5 Mil).
Enterprise Value is the theoretical takeover price. It is more comprehensive than market capitalization (market cap), which only includes common equity. Enterprise Value is calculated as the market cap plus debt and minority interest and preferred shares, minus total cash and cash equivalents. HeXun Biosciences Co's Enterprise Value for Today is NT$3,461.6 Mil.
HeXun Biosciences Co Market Cap Historical Data
The historical data trend for HeXun Biosciences Co's Market Cap can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Competitive Comparison of HeXun Biosciences Co's Market Cap
For the Biotechnology subindustry, HeXun Biosciences Co's Market Cap, along with its competitors' market caps and Market Cap data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
HeXun Biosciences Co's Market Cap Distribution in the Biotechnology Industry
For the Biotechnology industry and Healthcare sector, HeXun Biosciences Co's Market Cap distribution charts can be found below:
* The bar in red indicates where HeXun Biosciences Co's Market Cap falls into.
Market cap is the short version of market capitalization. It is the total market value to buy the whole company. It is equal to the share price times the number of shares outstanding.
HeXun Biosciences Co's Market Cap for the fiscal year that ended in Dec. 2024 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
HeXun Biosciences Co (ROCO:6986) Market Cap Explanation
Market cap is not the real price you pay for a company. If you buy the company and become its owner, you become the owner of the cash the company has, and you also assume the companys debt. The real price you pay is the Enterprise Value.
Warren Buffett uses the ratio of total market cap of all public traded companies over GDP to measure if the market is expensive. As of April 2012, the US total market cap is about $14.7 trillion, while the US GDP is about $15 trillion. The market was modestly overvalued.
HeXun Biosciences Co Market Cap Related Terms
Thank you for viewing the detailed overview of HeXun Biosciences Co's Market Cap provided by GuruFocus.com. Please click on the following links to see related term pages.
HeXun Biosciences Co Ltd is engaged in the research and development of cell drugs and cell derivatives. It conducts research and development jointly with medical research institutions to use stem cells to treat cardiovascular, immune-inflammatory, and neurodegenerative diseases to develop innovative cell drugs and treatment methods. The company's main business items are new drug research and development, biotechnology services, and research and development services, such as: commissioned research and development and production services for cell medicine, agency testing and development services, and biomedical consulting services, etc.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
ROCO:6986 has been successfully added to your